Tuesday, October 13, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 22, 2026

P&G Announces Fiscal Year 2026 Second Quarter Results

View original at finance.yahoo.com
P&G Announces Fiscal Year 2026 Second Quarter Results Net Sales +1%; Organic Sales 0% Diluted EPS $1.78, -5%; Core EPS $1.88, 0% UPDATES GAAP EPS FOR RESTRUCTURING OUTLOOK MAINTAINS FISCAL YEAR SALES, CORE EPS GROWTH AND CASH RETURN GUIDANCE CINCINNATI, January 22, 2026--(BUSINESS WIRE)--The Procter & Gamble Company (N…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • P&G's Q2 results keep the company on track to deliver within fiscal year guidance ranges for organic sales growth, core EPS growth and adjusted free cash flow productivity in a challenging consumer and geopolitical environment

    80% confidence
  • P&G's strategy is to reinvent P&G and create the CPG company of the future, delivering long-term balanced top- and bottom-line growth

    80% confidence
  • FY2026 core EPS growth guidance maintained at 0% to +4% (range $6.83 to $7.09)

    80% confidence
  • FY2026 diluted EPS growth revised down to +1% to +6% (from +3% to +9%) due to restructuring charges

    80% confidence
  • FX expected to provide $200M after-tax tailwind for FY2026

    80% confidence
  • P&G has confidence in plans to deliver stronger results in the second half of fiscal year 2026

    80% confidence
  • Commodity costs expected to be neutral for FY2026 (updated from prior forecast)

    80% confidence
  • Tariff costs expected to create $400M after-tax headwind for FY2026

    80% confidence
  • FY2026 organic sales growth guidance maintained at 0% to +4%

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com